Dispositions (Tables)

9 Months Ended

Sep. 30, 2017

Discontinued Operations and Disposal Groups [Abstract]

Major Classes of Assets Sold and Gain Recognized

The following table presents the impact the discontinuation and market withdrawal of Ionsys had on the Company’s statement of operations for the nine months ended September 30, 2017 (amounts in thousands):

Operating expenses:
Cost of product revenue	$	8,458
Asset impairment charges	264,097
Research and development	1,032
Selling, general and administrative	3,331
Total operating expenses	276,918
Loss from operations	(276,918		)
(Loss) income from continuing operations before income taxes	(276,918		)
Benefit (provision) for income taxes	—
Net (loss) income from continuing operations	$	(276,918	)

The following table presents the consideration received, major classes of assets sold and the gain recognized on the sale of the Non-Core ACC Products:

	(in thousands)
Sale price:
Cash	$	263,807
Contingent purchase price from sale of business	65,700
Total sale price	329,507
Assets:
Inventory	2,184
Intangibles	5,210
Goodwill	33,812
Total assets sold	41,206
Gain on sale of business	$	288,301

The following table presents key financial results of the Hemostasis Business included in “Income (loss) from discontinued operations, net of tax” for the three and nine months ended September 30, 2016:

	Three Months Ended September 30,			Nine Months Ended September 30,
	2016			2016
Net product revenues	$	28		$	78
Operating expenses:
Cost of product revenue	(9		)	1,695
Research and development	(15		)	104
Selling, general and administrative	(44		)	634
Total operating expenses	(68		)	2,433
Income (loss) from operations	96			(2,355		)
Gain from sale of business	—			1,004
Other expense, net	—			(39		)
Income (loss) from discontinued operations before income taxes	96			(1,390		)
Benefit for income taxes	—			—
Income (loss) from discontinued operations, net of tax	$	96		$	(1,390	)